Expert Insights: Navigating the Influx of New Therapies in Endometrial Cancer

In this episode, titled ‘Expert Insights: Navigating the Influx of New Therapies in Endometrial Cancer,’ the expert Oncology Pharmacists explored the following questions:

What role do oncology pharmacists play in evaluating emerging clinical evidence in endometrial cancer and making treatment recommendations to physicians?

How can pharmacists identify gaps between clinical guidelines and real-world practice in endometrial cancer treatment?

What is the role of the pharmacist in assessing immunotherapies for formulary placement in endometrial cancer?

Moderated by Megan May, the panel highlighted the critical skill set pharmacists bring to literature evaluation and clinical translation. Erin Zacholski discussed how pharmacists draw on experience with antibody-drug conjugates (ADCs) and immunotherapies from other disease states—such as breast and lung cancer—to anticipate toxicities like pneumonitis and nausea in the endometrial space. Justina Salib and the experts examined the "why" behind deviations from NCCN guidelines, noting that pharmacists often bridge gaps by incorporating Phase 1 and 2 data into institutional protocols. Furthermore, Jennifer MacDonald emphasized the pharmacist’s proactive role in formulary management, often being the first to trigger reviews and treatment plan builds following FDA approvals to ensure cutting-edge therapies are readily available for patients.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘The Science of Selection: Pharmacist Initiatives in Endometrial Cancer Care, features the panelists advancing their conversation on endometrial cancer and focusing on the implementation of biomarker-led education and the clinical management of immune-related adverse events.